Executive Summary : | The World Health Organization (WHO) and Global Cancer Observatory (GLOBOCAN) reported 2.3 million confirmed cases of breast cancer in 2020, resulting in 6,85,000 deaths globally. The death toll is higher in developing nations, and most of the patients are characterised by the triple-negative breast cancer (TNBC) subtype, making treatment difficult. Novel strategies are needed to eradicate TNBC. The utilization of two dimensional MXenes (2D MXenes) have been explored in biosensing, photobiological as well as electronics application. Moreover, design and fabrication of mesoporous silica framework (MSFs) being investigated for its multifunctional applications such as biosensing, catalysis, ceramics, drug delivery, etc. Highly porous nature of mesoporous silica offers greater drug loading as well as surface functionalization opportunities which can further tailored for various applications. Carbon dots (CDs) is a carbon-based fluorescent nanomaterials have been explored in various biomedical applications due to their excellent photophysical attributes. Furthermore, CDs have been reported to have excellent biocompatibility, in vivo-in vitro stability, and extremely low cytotoxicity, which facilitates their use in cellular bioimaging. Various natural phytochemicals, such as resveratrol, have been shown to improve chemo-resistance sensitization. The needs-driven focus of the current proposal is on the fabrication of surface functionalized MSFs that would serve as drug reservoirs. To prevent drug elution and CD desorption from MSF pores, drug-loaded MSFs embedded with CDs that will undergo post-functionalization (MSFs@CDs). Functionalized 2D MXenes will be utilized as template for controlled deposition of the MSFs@CDs to yield MSFs@CDs/MXenes complex. Proposed multifunctional nanoplatform for cancer theranostics offering targeted drug delivery, real-time imaging and greater in vivo - in vitro stability. The present strategy will be offer a combinational theranostic nanoplatform for guided tumor ablation with imaging and drug delivery. The Food and Drug Administration (FDA) has warned about the toxicity of traditional contrast agents on the kidneys. Therefore, exploration of MXenes (e.g. Ta4C3, and Lu2CT2) as magnetic resonance imaging (MRI) and x-ray radiography (CT) contrast agent will be a new avenue for tumor imaging. Besides, the present proposal has significant potentials in terms of patentability and scalability, considering the future demands for mesoporous silica in cargo delivery, ceramics, smart reservoirs, and novel MXenes applications in electronics, sensor development, photothermal applications, etc. The problems with existing nanoplatforms, such as poor cellular uptake, toxicity and in vitro - in vivo stability will be resolved with the present proposal. Moreover, the present proposal has potential for patentability and scalability, considering the future demands for mesoporous silica and novel lanthanide MXenes. |